Achieving Highest Complete Remission Rate of Any Lupus study
- Low dose voclosporin achieves CR rate of 49.4% at 48 weeks (p<.001)
- AURORA Phase III trial with low dose voclosporin on track to commence in Q2 2017
ir.auriniapharma.com/press-releases/detail/73
seekingalpha.com/article/4051484-aurinia-successful-48-week-phase-2b-trial-results-even-better-expected
- AURORA Phase III trial with low dose voclosporin on track to commence in Q2 2017
ir.auriniapharma.com/press-releases/detail/73
seekingalpha.com/article/4051484-aurinia-successful-48-week-phase-2b-trial-results-even-better-expected
免責聲明
這些資訊和出版物並不意味著也不構成TradingView提供或認可的金融、投資、交易或其他類型的意見或建議。請在使用條款閱讀更多資訊。